wepbound.com

Tag: investment strategy

  • **Is It Good to Invest in an Innovation Fund? The Data, Risks, and Real Returns**

    **Is It Good to Invest in an Innovation Fund? The Data, Risks, and Real Returns**

    Header image: Bioscience Innovation Act bill signing ceremony (9672310549).jpg) by Dannel Malloy, CC BY 2.0, via Wikimedia Commons — cropped to 16:9 and colour-adjusted.

    Key takeaways

    • Innovation funds can outperform indices but require long-term commitment and risk tolerance.
    • Domestic funds like ICICI Pru focus on Indian innovation, while global funds offer broader exposure.
    • Allocate only 3-5% of your portfolio to innovation funds as a satellite holding.

    Here’s the short answer: Yes, but only if you meet very specific conditions. Innovation funds can deliver outsized returns—Kotak Pioneer Fund returned 36.4% over three years compared to 31.75% for the Nifty 500 TRI—but they are not "safe" investments. Their success depends on geographic diversification, stage-specific bets, manager expertise, and your ability to stomach volatility. If you’re not prepared for 20–30% drawdowns, lack a 5–10+ year horizon, or haven’t already maxed out diversified funds like index funds, walk away. For everyone else, innovation funds belong as a small satellite holding—think 3–5% of your portfolio, not the core.

    The Surge in Innovation Funds: Why 2024 Is Different

    April 2024 saw a flurry of innovation fund launches: ICICI Prudential, Bandhan Mutual Fund, and Nippon Life all rolled out new offerings. This wasn’t random timing. The Federal Reserve and RBI are normalizing interest rates, and history shows that lower rates favor growth stocks—exactly the kind of companies innovation funds target.

    But here’s the catch: These 2024 launches are overwhelmingly domestic-focused. ICICI Pru’s Innovation Fund, for example, is "more domestic-focused" according to critics, despite allowing overseas securities. Bandhan’s fund doesn’t even disclose its allocation strategy. Meanwhile, three global ‘fund of funds’ (Axis, DSP and Kotak) already exist, offering broader exposure to global innovators. The domestic funds? They’re betting on Indian companies adopting innovation, not necessarily global leaders driving it.

    How These Funds Are Structured

    • ICICI Pru Innovation Fund:
    • Minimum 80% in innovation-adopting companies, including overseas securities.
    • Targets three stages of innovation:
    1. Initial research/product development (highest risk, e.g., unproven biotech).
    2. Pre-launch/testing (moderate risk, e.g., beta-stage SaaS).
    3. Launch/post-launch (lower risk, e.g., scaling fintech).
    • Nippon Life Innovation Fund:
    • Multi-cap, with a bias toward low-leverage, high-profitability growth firms. This reduces bankruptcy risk but may exclude cash-burning disruptors (e.g., early-stage EV startups).
    • Bandhan Innovation Fund:
    • Launched the same day as ICICI Pru’s NFO (April 10, 2024), but no specifics on allocation or strategy have been disclosed.

    The takeaway? If you’re going to invest, scrutinize the fund’s exposure. Domestic-only funds are narrower and riskier than global ones, and stage-specific bets (early vs. late) drastically alter the risk/reward profile.

    Where Innovation Funds Win: The Outperformance Case

    The strongest argument for innovation funds is their potential to outperform broad-market indices. Kotak Pioneer Fund’s 36.4% 3-year return (vs. 31.75% for the Nifty 500) isn’t an anomaly—it’s a proof point that targeted innovation exposure can work.

    Three Key Advantages

    1. Access to Early-Stage Disruptors
    • ICICI Pru’s fund includes pre-launch/testing-stage companies, which are high-risk but high-reward. Think of a startup with a breakthrough AI model—unproven but potentially revolutionary.
    • Nippon Life’s low-leverage, high-profitability filter may reduce bankruptcy risk while still capturing scaling innovators (e.g., profitable SaaS companies).
    1. Diversification Within Innovation
    • Unlike single-sector funds (e.g., pure-play AI ETFs), innovation funds span multiple themes—AI, biotech, fintech, cleantech. This reduces sector-specific risk (e.g., if biotech crashes but AI soars).
    1. Thematic Tailwinds
    • Innovation isn’t cyclical—it’s structural. AI, automation, and biotech are long-term trends, not fads. Funds that get in early (like Kotak Pioneer did in 2019) can ride these waves for years.

    Real-World Example: Fundrise Innovation Fund

    • Open to all US investors (not just accredited).
    • One investor allocated 3.5% of their portfolio to it and called it "a worthwhile investment"—their largest gains came from this fund.
    • Unlike Indian funds, Fundrise blends public and private innovation bets, giving exposure to pre-IPO disruptors.

    Where Innovation Funds Fall Short: The Hard Truths

    For every success story, there’s a hidden risk—and innovation funds have plenty.

    1. Narrow Focus = Higher Volatility

    • Thematic funds underperform in downturns. In 2022, tech-heavy innovation funds crashed harder than the Nifty 500. If you can’t stomach a 20–30% drawdown, you’re not cut out for this.
    • No international exposure in domestic funds is a major flaw. Critics argue Nippon Life’s fund should include US cutting-edge companies.g., Nvidia, Moderna). Missing global leaders means missing the biggest innovators.**

    2. Liquidity Risks

    • Innovation funds are intended as long-term investments with less liquid assets than diversified funds. Fundrise, for example, holds private companies—you can’t sell those overnight.
    • If you might need cash in less than 5 years, this isn’t the place for it.

    3. Manager Dependency

    • "Any fund is only as good as the people managing it. " This isn’t just criticism—it’s reality. Poor stock-picking can erase alpha. For example:
    • If ICICI Pru’s fund bets heavily on failed startups, returns will suffer.
    • Nippon Life’s profitability filter might exclude high-growth, cash-burning disruptors (e.g., early-stage EV companies).

    4. Timing Risk

    These funds launched in 2024 as a normalising interest rate environment appears on the cards. What happens if rates stay high? Growth stocks suffer. 2022 proved that.**

    Geographic Exposure: The Domestic vs. Global Divide

    | Fund | Overseas Exposure? | Pros | Cons | |———————–|——————–|——————————-|——————————-| | ICICI Pru Innovation | Yes (but domestic-focused) | Avoids currency risk | Misses global leaders (Nvidia, Moderna) | | Bandhan Innovation | Unknown | Simpler regulatory hurdles | Likely no global exposure | | Nippon Life Innovation | No | Lower geopolitical risk | Critics would have liked to add overseas exposure to companies in cutting-edge spaces in the US | | Kotak Pioneer | Via fund structure | Access to innovation funds | Higher fees, currency risk | | Fundrise (US) | Yes (US-focused) | Blends public/private bets | Illiquid private holdings |

    The verdict?

    • If you want pure innovation exposure, global funds (Kotak, Fundrise) are stronger.
    • If you prefer simplicity and lower fees, domestic funds (ICICI Pru, Nippon) are an option—but you’re sacrificing global leaders.

    Stage-Specific Bets: How Much Risk Are You Taking?

    ICICI Pru’s three-stage framework is a masterclass in risk stratification. Here’s how it breaks down:

    | Stage | Risk Level | Example | Upside Potential | |—————————|————|—————————–|——————| | Initial research/product development | Highest | Unproven biotech startup | 10x+ if successful | | Pre-launch/testing | Moderate | Beta-stage SaaS company | 3–5x | | Launch/post-launch | Lower | Scaling fintech | 2–3x |

    Nippon Life’s approach is different:

    • Low leverage + high profitability = reduced bankruptcy risk.
    • But it may exclude cash-burning disruptors (e.g., early-stage EV companies).

    The trade-off?

    • Early-stage = higher upside but higher failure rate.
    • Post-launch = steadier but less alpha.

    Which is better? It depends on your risk tolerance. If you want home-run potential, early-stage is key. If you prefer lower volatility, post-launch is safer.

    The Competition: How Do These Funds Stack Up?

    | Fund | Launch Date | Min. Allocation to Innovation | Overseas Exposure? | Stage Focus | 3-Year Return (if available) | |———————–|————-|——————————-|——————–|———————-|——————————| | ICICI Pru Innovation | Apr 2024 | 80% | Yes (but domestic-focused) | All three stages | N/A | | Bandhan Innovation | Apr 2024 | N/A | Unknown | Unknown | N/A | | Nippon Life Innovation | 2024 | N/A | No | Multi-cap, growth | N/A | | Kotak Pioneer | Oct 2019 | N/A | Unknown | Unknown | 36.4% | | Fundrise Innovation | Unknown | Unknown | Yes (US-focused) | Unknown | Top performer for one investor |

    Key takeaways:

    • Global funds (Kotak, Fundrise) offer broader exposure but come with higher fees and currency risk.
    • Domestic funds (ICICI Pru, Nippon) are narrower but simpler—but critics argue they miss global leaders.
    • Stage-specific funds (ICICI Pru) let you choose your risk level, while profitability-focused funds (Nippon) reduce bankruptcy risk.

    The Investor Profile: Who Should (and Shouldn’t) Invest?

    ✅ Good Fit If You:

    • Have a 5–10+ year horizon (innovation is a long game).
    • Can handle 20–30% drawdowns (e.g., 2022’s tech crash).
    • Allocate less than 5% of your portfolio (e.g., the 3.5% Fundrise investor).
    • Already maxed out diversified funds (e.g., Nifty 500 index).

    ❌ Bad Fit If You:

    • Need liquidity (innovation funds are illiquid).
    • Are risk-averse (these are not "safe" investments).
    • Lack manager trust (poor stock-picking kills returns).
    • Haven’t diversified your core holdings (innovation funds are satellite holdings, not replacements for index funds).

    The Bottom Line: How to Invest in Innovation (If at All)

    If you’re still reading, you’re serious about innovation funds. Here’s how to do it right:

    1. Pick Global Exposure (If Possible)

    • Kotak Pioneer Fund (via FoF) or Fundrise Innovation Fund (US-focused) give you global leaders (Nvidia, Moderna, etc.).
    • If you must go domestic, ICICI Pru’s fund (which allows overseas securities) is the best option.

    2. Diversify Across Innovation Stages

    • ICICI Pru’s three-stage approach lets you balance early-stage risk with post-launch stability.
    • If you want lower volatility, Nippon Life’s profitability filter reduces bankruptcy risk.

    3. Limit to 3–5% of Your Portfolio

    • Innovation funds are high-risk, high-reward. 3.5% (like the Fundrise investor) is a smart allocation—enough to move the needle, but not enough to wipe you out.

    4. Check the Manager’s Track Record

    • "Any fund is only as good as the people managing it. " Look for:
    • Past performance (e.g., Kotak Pioneer’s 36.4% return).
    • Sector expertise (does the team understand AI, biotech, etc.?).
    • Risk management (does the fund avoid reckless bets?).

    Alternatives to Consider

    If innovation funds feel too risky, here are lower-risk ways to play innovation:

    • Diversified growth funds (e.g., Nifty Next 50) for broader exposure.
    • Sector-specific ETFs (e.g., AI, biotech) for targeted bets.
    • Venture capital (VC) funds (if accredited) for higher-risk, higher-reward private innovation.

    Final Question: Is the Juice Worth the Squeeze?

    Innovation funds can outperform—but only under the right conditions. If you:

    • Have a long time horizon,
    • Can stomach volatility,
    • Allocate wisely (3–5%), and
    • Pick the right fund (global exposure, strong manager),

    …then yes, they’re worth it.

    But if you’re looking for stability, liquidity, or "safe" returns, keep walking. Innovation funds are not for the faint of heart—they’re for investors who understand the risks and can afford to wait.

    So, is it good to invest in an innovation fund? Only if you’re prepared to lose money for years before (hopefully) winning big. If that’s not you, stick to index funds. If it is? Dive in—but not with more than 5% of your portfolio. The real question is: Are you ready for the ride?

    Sources

  • **How Does a General Partner Get Paid? The Evidence Behind Private Equity and VC Compensation**

    **How Does a General Partner Get Paid? The Evidence Behind Private Equity and VC Compensation**

    Header image source: What is a General Partnership? via Sul Lee Law Firm via Google — cropped to 16:9 and colour-adjusted.

    Key takeaways

    • GPs earn via management fees (percentage of committed capital) and carried interest (share of profits after LPs are repaid)
    • Hurdle rates and clawbacks protect LPs from premature or excessive carry payouts
    • LP negotiating power shapes fee structures, especially for top-tier funds with strong track records

    General partners get paid in two ways: management fees and carried interest. Straightforward, but not simple. The first is a percentage of committed capital, paid annually. The second is a share of profits—after limited partners get their money back. That’s the standard model. It’s everywhere. Top-tier firms use it. Funds across the industry use it. It’s the industry’s default because it works: predictable cash flow for the GP, skin in the game for returns.

    Management fees are paid regardless of fund performance. No carry. If the fund performs well, the GP receives a share of the profits. That’s the deal.

    Management Fees: The Engine That Keeps the Lights On

    Management fees are the salary of private equity and venture capital. A percentage of committed capital, paid annually. But the number isn’t fixed. Early-stage VC funds often charge higher percentages—the amount varies based on fund size and operational needs. Larger funds with substantial assets under management can negotiate lower percentages. The dollar amount still covers overhead.

    These fees aren’t profit. They’re operational budget. Management fees cover operational costs including salaries, office expenses, travel, and professional services. The money flows from limited partners, typically on a periodic basis. LPs don’t love writing these checks. They’re pure expense. But they accept them because without the fee, the GP can’t function.

    The fee is also a signal. A fund that reduces its management fee significantly may signal different priorities to LPs. That spooks LPs. Many funds maintain standard fee structures even when adjustments might be possible.

    Carried Interest: The Performance Bonus That Can Make or Break a GP’s Net Worth

    Carried interest represents a significant portion of GP compensation when funds perform well. It’s a share of the fund’s profits—but only after LPs get their capital back. That’s the profit split. But it’s not that simple. Many funds include a hurdle rate. Until LPs receive their capital back plus that 8% return, the GP gets nothing.

    Here’s how it works. Consider a hypothetical fund. After some time, the portfolio appreciates. The initial capital is returned to LPs. The hurdle rate return also goes to LPs. Only then does the GP start collecting carry. The remaining profits are split between LPs and the GP. That amount represents carried interest. It’s taxed as long-term capital gains, which typically has a lower rate than ordinary income.

    That tax treatment is why carried interest is politically contentious. Some critics argue it provides favorable treatment. Some defend the tax treatment by arguing carry is an investment return rather than compensation.

    Carry isn’t paid in a lump sum. It’s distributed as portfolio companies achieve liquidity events. When a fund sells a company, the GP may receive a share of the profit if the fund has met its hurdle requirements. If not, the GP gets nothing, and LPs keep the whole payout.

    This creates a perverse incentive. The timing of carry distributions can influence GP decision-making regarding exits. That’s why some funds add clawback provisions. Clawback provisions require GPs to return excess carry if overall fund performance doesn’t justify it.

    The Catch: Clawbacks and Hurdle Rates

    Clawbacks and hurdle rates keep general partners from getting too greedy. A hurdle rate ensures LPs earn a minimum return before the GP receives carry. Without a hurdle rate, a fund could pay carry even when LPs haven’t achieved satisfactory returns.

    Clawbacks are the safety net for LPs. Consider a scenario where a fund exits an investment profitably and pays carry to the GP. If the remaining portfolio underperforms and the fund’s overall returns are insufficient. The GP would owe money back to LPs because the early carry exceeded what was justified by overall fund performance.

    Most funds include both hurdles and clawbacks, but enforcement is messy. Clawback calculations can be complex. Tax considerations can affect clawback amounts.8 million back, not $6 million. That’s a material difference. Some LPs prefer clawback structures that account for tax implications differently. Clawbacks are intended to protect LPs from overpayment of carry, but the exact terms are negotiated fund by fund.

    How GPs Actually Spend Their Time (And What It Means for Compensation)

    General partners don’t spend their days hunched over spreadsheets. Their time is split between three activities: fundraising, LP relations, and media appearances.

    Fundraising is critical. Management fees are a percentage of committed capital. Every extra dollar raised directly increases the GP’s fee income. Additional capital raised increases the GP’s fee income proportionally. These fees support the fund’s operations and compensation.

    LP relations come next. GPs maintain relationships with existing LPs through various communications. Happy LPs re-up in the next fund. Unhappy LPs pull their capital. That can kill a fund before it starts investing.

    The third activity is media and thought leadership. High-profile GPs use visibility to attract deal flow. Visibility can contribute to fund performance and terms.

    Board seats are a formality. GPs take them, but they’re rarely hands-on. Junior partners or principals typically handle the day-to-day operational aspects. The GP’s role is strategic rather than operational. That’s why GPs can manage multiple boards simultaneously. They’re allocators, not operators.

    The GP-LP Power Dynamic: Who Really Controls Compensation?

    Limited partners have more leverage than most people realise. The standard structure is common but not immutable. Large institutional investors negotiate fee structures, hurdle rates, and clawback terms. Some large institutional investors demand favorable terms. Top-tier firms with strong track records can command better terms.

    Industry data shows most funds maintain standard fee and carry structures. The exceptions prove the rule. Seed-stage funds often charge higher fees because their asset base is smaller. Hedge funds often use different fee structures that reflect their operational needs. Some evergreen funds don’t charge carry. They take equity stakes instead. That works for certain structures but wouldn’t scale to large private equity funds.

    The power dynamic shifts with fund performance. A first-time GP raising a smaller fund has limited leverage. They’ll take whatever terms LPs offer. A GP with a successful track record can negotiate better terms. That’s why the industry is reputation-driven. Past performance is the only currency that matters.

    Alternative Models: When the 2-and-20 Rule Doesn’t Apply

    The standard model dominates, but it’s not universal. Seed-stage funds often charge higher fees because their asset base is smaller. Micro-funds may need higher fees to cover operational costs. Hedge funds often use different fee structures that reflect their operational needs.

    Evergreen funds operate without carry entirely. Some evergreen funds don’t charge management fees or carry. It takes equity stakes instead. That works for certain structures but wouldn’t scale to large private equity funds. The equity stakes would be too small to generate meaningful returns.

    Some funds experiment with fee adjustments based on performance. If a fund generates carry, the GP might adjust future fees accordingly. That aligns incentives further, but it’s rare. It complicates cash flow.

    The most radical alternative is the “no-fee” model. The GP takes no management fees and relies entirely on carry. Common in angel investing, but almost unheard of in institutional funds. It leaves the GP with no income until exits start rolling in—sometimes years after the fund is raised.

    The Big Picture: Why This Compensation Model Dominates

    The standard model persists because it works. Management fees provide stable income to run the fund. Carried interest aligns the GP’s interests with the fund’s performance. If the fund loses money, the GP still collects fees but walks away with zero carry. If the fund performs well, the GP receives a share of the profits.

    The criticisms are valid. High fees eat into LP returns. The tax treatment of carried interest remains politically contentious. Some funds experiment with performance-based adjustments to fee structures. But these tweaks are marginal. The core model isn’t going anywhere.

    The real question isn’t whether the standard model will survive. It’s whether the next generation of GPs can justify the fees in a world where LPs demand more transparency, lower costs, and better alignment. The answer will determine who gets paid, and how much.

    Sources